<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30845175</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Efficient expression of enterovirus 71 based on virus-like particles vaccine.</ArticleTitle><Pagination><StartPage>e0210477</StartPage><MedlinePgn>e0210477</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0210477</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0210477</ELocationID><Abstract><AbstractText>Enterovirus (EV) 71 is the main pathogen associated with hand-foot-mouth disease (HFMD) and can lead to the disease with severe mortality in children. Since 2009, in the Republic of Korea, an outbreak of EV71 C4a infection with neurologic involvement emerged, where in HFMD involvement was identified and central nervous system complications were reported. In this study, EV71 C4a virus-like particles (VLPs) produced by recombinant technology were generated in a baculovirus expression system. To improve the production yield, EV71 VLP was constructed using the dual promoter system baculovirus P1 and 3CD (baculo-P1-3CD), which harbored both the structural protein-encoding P1 region under the control of the polyhedron promoter and the 3CD protease gene under the regulation of the CMV-IE, lef3, gp41, or chitinase promoters to augment the level of gene transcription. Efficient VLP expression was demonstrated through optimization of incubation time and insect cell type. In addition, to evaluate the potential of VLP as a vaccine candidate, we tested the neutralizing antibodies and total anti-EV71 IgG from the purified EV71 C4a VLP serum. The recombinant EV71 VLP exhibited the morphology of self-assembled VLP, as determined by electron microscopy. Use of baculo-P1-3CD-gp41 led to a high yield (11.3mg/L &lt; 40kDa) of VLPs in High-FiveTM cells at 3 days post-infection. Furthermore, the potential of VLP as a vaccine was evaluated through the neutralizing ability elicited by the purified EV71 VLP after immunization of BALB/c mice, which was shown to induce potent and long-lasting humoral immune responses as evidenced by the cross-neutralization titer. Our results could be used to expedite the developmental process for vaccines under clinical trials and to ensure manufacturing consistency for licensing requirements.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hye-Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Ho Sun</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang Won</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Division of Strategic Planning for Emerging Infectious Disease, Centers for Disease Control and Prevention, Osong, CheongJu, Chungcheongbuk-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Youngsil</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Viral Disease, Center for Laboratory control of Infectious Disease, Centers for Disease Control and Prevention, Osong, CheongJu, Chungcheongbuk-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyeon</LastName><ForeName>Ji-Yeon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Gyung Tae</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Division of Strategic Planning for Emerging Infectious Disease, Centers for Disease Control and Prevention, Osong, CheongJu, Chungcheongbuk-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>June-Woo</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-2923-5597</Identifier><AffiliationInfo><Affiliation>Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jung Sik</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Division of Vaccine Research, Center for Infectious Diseases, Korea National Institutes of Health, Korea Centers for Disease Control and Prevention, Osong-eup, Cheongju, Chungcheongbuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061987" MajorTopicYN="N">Sf9 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>3</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30845175</ArticleId><ArticleId IdType="pmc">PMC6405078</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0210477</ArticleId><ArticleId IdType="pii">PONE-D-18-25927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 1995;39:195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008;26:1855&#x2013;62. 10.1016/j.vaccine.2008.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoll GJ, Melchers WJ, Kopecka H, Jambroes G, van der Poel HJ, Galama JM. General primer-mediated polymerase chain reaction for detection of enteroviruses: application for diagnostic routine and persistent infections. J ClinMicrobiol 1992;30:160&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC265013</ArticleId><ArticleId IdType="pubmed">1370845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J Clin Microbiol 2006;44:2698&#x2013;704. 10.1128/JCM.00542-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00542-06</ArticleId><ArticleId IdType="pmc">PMC1594621</ArticleId><ArticleId IdType="pubmed">16891480</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, Earl P, et al.Molecular epidemiology of human enterovirus 71 in theUnited Kingdom from 1998 to 2006. J Clin Microbiol 2008;46:3192&#x2013;200. 10.1128/JCM.00628-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00628-08</ArticleId><ArticleId IdType="pmc">PMC2566106</ArticleId><ArticleId IdType="pubmed">18650362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YF, Sam IC, AbuBakar S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 2010;10:404&#x2013;12. 10.1016/j.meegid.2009.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2009.05.010</ArticleId><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, Lin KH, et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 2009;47:3653&#x2013;62. 10.1128/JCM.00630-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00630-09</ArticleId><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010;10:778&#x2013;90. 10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J 2013;6:19780 10.3402/ehtj.v6i0.19780</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, et al. The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008. PLoS One 2011;6:e25662 10.1371/journal.pone.0025662</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025662</ArticleId><ArticleId IdType="pmc">PMC3181342</ArticleId><ArticleId IdType="pubmed">21980521</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu WS, Kang B, Hong J, Hwang S, Kim A, Kim J, et al. Enterovirus 71 infection with central nervous system involvement, South Korea. Emerg Infect Dis 2010;16:1764&#x2013;6. 10.3201/eid1611.100104</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1611.100104</ArticleId><ArticleId IdType="pmc">PMC3294506</ArticleId><ArticleId IdType="pubmed">21029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Lu J, Lu J. Enterovirus 71 vaccine: close but still far. Int J Infect Dis 2010;14:e739&#x2013;43. 10.1016/j.ijid.2009.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2009.12.002</ArticleId><ArticleId IdType="pmc">PMC7110504</ArticleId><ArticleId IdType="pubmed">20400350</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Meng FY, Mao Q, Li JX, Wang H, Liang ZL,et al.Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother 2014;10:1366&#x2013;72. 10.4161/hv.28397</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28397</ArticleId><ArticleId IdType="pmc">PMC4896521</ArticleId><ArticleId IdType="pubmed">24633366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother 2012;8:1775&#x2013;83. 10.4161/hv.21739</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Benen TD, Tonks P, Kliche A, Kapzan R, Heeney JL, Wagner R. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci 2014;21:79 10.1186/s12929-014-0079-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-014-0079-x</ArticleId><ArticleId IdType="pmc">PMC4256929</ArticleId><ArticleId IdType="pubmed">25160824</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J 2010;7:279 10.1186/1743-422X-7-279</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-279</ArticleId><ArticleId IdType="pmc">PMC2984592</ArticleId><ArticleId IdType="pubmed">20961433</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014;384:2046&#x2013;52. 10.1016/S0140-6736(14)61185-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)61185-5</ArticleId><ArticleId IdType="pubmed">25132507</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. 2011 Sci Transl Med 2011;3:94ra71 10.1126/scitranslmed.3002330</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002330</ArticleId><ArticleId IdType="pubmed">21813755</ArticleId></ArticleIdList></Reference><Reference><Citation>Betenbaugh M, Yu M, Kuehl K, White J, Pennock D, Spik K, et al. Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus. Virus Res 1995;38:111&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8578853</ArticleId></ArticleIdList></Reference><Reference><Citation>Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011;3:174&#x2013;96. 10.1002/wnan.119</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.119</ArticleId><ArticleId IdType="pmc">PMC7169818</ArticleId><ArticleId IdType="pubmed">20872839</ArticleId></ArticleIdList></Reference><Reference><Citation>Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008;2:97&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727782</ArticleId><ArticleId IdType="pubmed">19707432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Lu X, Li S, Fang M, Zhang J, Xia N, et al.Lessons learned from successful human vaccines: delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother 2015;11:1277&#x2013;92. 10.1080/21645515.2015.1016675</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1016675</ArticleId><ArticleId IdType="pmc">PMC4514273</ArticleId><ArticleId IdType="pubmed">25751641</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa T, Ritter DG, Roy P. Expression of largest RNA segment and synthesis of VP1 protein of bluetongue virus in insect cells by recombinant baculovirus: association of VP1 protein with RNA polymerase activity. Nucleic Acids Res 1989;17:7395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC334818</ArticleId><ArticleId IdType="pubmed">2552409</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xe4;utigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology 1993;192:512&#x2013;24. 10.1006/viro.1993.1067</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1067</ArticleId><ArticleId IdType="pubmed">8380663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Huang JH, Lai CW, Sheng HC, Shih SR, Ho MS, et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol 2006;12:921&#x2013;7. 10.3748/wjg.v12.i6.921</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v12.i6.921</ArticleId><ArticleId IdType="pmc">PMC4066158</ArticleId><ArticleId IdType="pubmed">16521221</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, et al. Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield. Vaccine 2010;28:6951&#x2013;7. 10.1016/j.vaccine.2010.08.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.052</ArticleId><ArticleId IdType="pubmed">20797455</ArticleId></ArticleIdList></Reference><Reference><Citation>Son H, Jeong HS, Cho M, Lee J, Lee H, Yoon K, et al. Seroepidemiology of predominant norovirus strains circulating in Korea by using recombinant virus-like particle antigens. Foodborne Pathog Dis 2013;10:461&#x2013;6. 10.1089/fpd.2012.1300</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/fpd.2012.1300</ArticleId><ArticleId IdType="pubmed">23627928</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang SS, Chang IS, Huang LW, Chen PC, Wen CC, Liu SC, et al. Temporal transcription program of recombinant Autographa californica multiple nucleopolyhedrosis virus. J Virol 2006;80:8989&#x2013;99. 10.1128/JVI.01158-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01158-06</ArticleId><ArticleId IdType="pmc">PMC1563934</ArticleId><ArticleId IdType="pubmed">16940511</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Guo MS, Lin FH, Hsiao KN, Chang KH, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 2011;6:e20005 10.1371/journal.pone.0020005</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020005</ArticleId><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M, Roos R. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, In: Knipe DM, Howley PM, editors. Fields virology. 5th ed, Philadelphia: Lippincott Williams and Wilkins;2007, p. 839&#x2013;93.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>